207.49 USD
+3.15
1.54%
At close Dec 20, 4:00 PM EST
After hours
207.49
+0.00
0.00%
1 day
1.54%
5 days
-2.86%
1 month
-2.24%
3 months
-12.44%
6 months
-5.39%
Year to date
-4.42%
1 year
-3.47%
5 years
38.47%
10 years
211.64%
 

About: Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Employees: 18,179

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

502% more call options, than puts

Call options by funds: $18.1M | Put options by funds: $3.01M

9% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 70

2% more capital invested

Capital invested by funds: $21.7B [Q2] → $22.3B (+$531M) [Q3]

1% more funds holding

Funds holding: 740 [Q2] → 746 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]

6.22% less ownership

Funds ownership: 100.55% [Q2] → 94.32% (-6.22%) [Q3]

19% less repeat investments, than reductions

Existing positions increased: 245 | Existing positions reduced: 301

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$260
25%
upside
Avg. target
$262
26%
upside
High target
$265
28%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
JMP Securities
David Turkaly
29% 1-year accuracy
7 / 24 met price target
28%upside
$265
Market Outperform
Reiterated
18 Nov 2024
Stephens & Co.
Jacob Johnson
47% 1-year accuracy
8 / 17 met price target
25%upside
$260
Overweight
Reiterated
7 Nov 2024
Piper Sandler
Jason Bednar
50% 1-year accuracy
19 / 38 met price target
25%upside
$260
Overweight
Upgraded
24 Oct 2024

Financial journalist opinion

Based on 3 articles about STE published over the past 30 days

Positive
Zacks Investment Research
4 days ago
Reasons to Retain STE Stock in Your Portfolio Now
STERIS' strong prospects in the healthcare business bode well for investors.
Reasons to Retain STE Stock in Your Portfolio Now
Positive
Zacks Investment Research
1 week ago
Why Is Steris (STE) Up 0.9% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Why Is Steris (STE) Up 0.9% Since Last Earnings Report?
Positive
Zacks Investment Research
3 weeks ago
New Alliances to Support STERIS Stock Despite Macro Issues
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
New Alliances to Support STERIS Stock Despite Macro Issues
Positive
Seeking Alpha
1 month ago
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business.
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Neutral
Zacks Investment Research
1 month ago
Why Steris (STE) International Revenue Trends Deserve Your Attention
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Why Steris (STE) International Revenue Trends Deserve Your Attention
Neutral
Seeking Alpha
1 month ago
STERIS plc (STE) Q2 2025 Earnings Call Transcript
STERIS plc (STE) Q2 2025 Earnings Call Transcript
STERIS plc (STE) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
1 month ago
Steris (STE) Surpasses Q2 Earnings Estimates
Steris (STE) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to earnings of $2.03 per share a year ago.
Steris (STE) Surpasses Q2 Earnings Estimates
Positive
Reuters
1 month ago
Steris beats quarterly estimates on continued demand for medical procedures
Medical equipment maker Steris beat second-quarter profit estimates on Wednesday, on continued demand for non-urgent medical procedures that boosted sales of its surgical and examination tools.
Steris beats quarterly estimates on continued demand for medical procedures
Charts implemented using Lightweight Charts™